immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules TCER®. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.
Quick Facts:150 Team members >100 Targets covering 20 major solid and liquid tumors About 80% of discovered targets are novel 2 proprietary technology platforms 8 proprietary development programs, thereof 3 in the clinic Multiple partnered programs Raised more than $230m in cash in five financings
- The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored by Perceptive Advisors, was completed on…
New York, NY, Houston, TX and Tuebingen, Germany, June 29, 2020 – Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition…
Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics
Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
- Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account